Advertisement
Advertisement
U.S. markets open in 2 hours 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
35.09-1.96 (-5.29%)
At close: 04:00PM EST
35.25 +0.16 (+0.46%)
After hours: 04:09PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close37.05
Open36.46
Bid0.00 x 1300
Ask0.00 x 800
Day's Range34.98 - 37.07
52 Week Range30.12 - 58.35
Volume235,531
Avg. Volume255,568
Market Cap2.052B
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XNCR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xencor, Inc.
    XNCR: Rating decreased to a HOLDXENCOR INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    14 days agoArgus Research
View more
  • Business Wire

    Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

    MONROVIA, Calif., January 11, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.

  • Business Wire

    Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

    MONROVIA, Calif., January 06, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.

  • Business Wire

    Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

    MONROVIA, Calif., December 12, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poste

Advertisement
Advertisement